CancerFax
ALL · CAR-T BRIDGE TRANSPLANT GUIDE

CAR-T AS BRIDGE TO
HAPLOIDENTICAL TRANSPLANT: PKUPH

CAR-T achieves remission. Transplant locks it in. And PKUPH's haploidentical programme means almost every patient has a donor.

Send Your ReportsContact Us

analyticsAt a Glance

  • check_circleCAR-T without transplant consolidation has significantly higher relapse rates in adult ALL than CAR-T + transplant
  • check_circlePKUPH runs Asia's largest allogeneic transplant programme — specialising in haploidentical (half-matched family donor) SCT
  • check_circleThe Peking Protocol enables haplo-SCT with parent, sibling, or child as donor — virtually all patients have a family donor
  • check_circleCancerFax manages the complete CAR-T → PKUPH transplant pathway for international patients
Reviewed by: CancerFax Medical Team, Oncology & Haematology SpecialistsLast reviewed: June 5, 2026

Why Transplant After CAR-T — Not Just CAR-T Alone?

CAR-T therapy achieves MRD-negative complete remission in 70–90% of patients with r/r B-cell ALL — a remarkable result in patients who have failed multiple prior therapies. However, without subsequent allogeneic transplant consolidation, the majority of adult patients relapse within 12 months. CAR-T as a single treatment course, without transplant, cures a minority of adult ALL patients. The combination of CAR-T to achieve remission followed by allo-SCT to consolidate it is the current standard for eligible patients.

“CAR-T clears the leukaemia. Transplant replaces the immune system that let it grow. Together, they offer something neither achieves alone.”

  • Why CAR-T Alone Is Insufficient for Most Adults

    CAR-T cells have a finite lifespan — persistence for 1–2 years in most patients. When CAR-T cells wane or become exhausted, residual leukaemia cells that survived at low levels (MRD) can re-emerge. Without the ongoing immune surveillance of an allogeneic graft and its graft-versus-leukaemia (GvL) effect, relapse rates are 50–70% in adult ALL without transplant consolidation.

  • The Graft-versus-Leukaemia Effect

    Donor immune cells in an allogeneic graft continuously survey the recipient's body for leukaemia cells — a phenomenon called graft-versus-leukaemia (GvL). This ongoing immune pressure, absent in CAR-T alone, provides durable anti-tumour protection long after CAR-T cells have waned. GvL is the reason allo-SCT produces long-term cure in ALL — and why it complements rather than competes with CAR-T.

CAR-T + Haploidentical Transplant: Key Outcomes

Published PKUPH data and international series quantify the survival benefit of transplant consolidation after CAR-T-induced remission in r/r ALL.

  • 50–65%2-year OS in r/r ALL patients achieving CAR-T CR and proceeding to allo-SCTPKUPH and collaborative Chinese series: patients who achieve MRD-negative CR with CAR-T and consolidate with haploidentical SCT achieve 2-year OS of 50–65% — substantially better than historical outcomes for r/r ALL.
  • 15–25%2-year OS in r/r ALL patients with CAR-T CR but no transplant consolidationWithout allo-SCT, despite initial MRD-negative CR, most adult ALL patients relapse — 2-year OS is 15–25% in CAR-T-only series, confirming transplant consolidation provides clinically essential durability.
  • >95%Patients with family donor for haploidentical SCT — virtually no donor shortageThe Peking Protocol enables SCT using a half-matched (haploidentical) parent, sibling, or child as donor — essentially eliminating donor shortage as a barrier to transplant. >95% of patients have at least one family donor.

The Peking Protocol: What It Is and Why It Changed Transplant Practice

PKUPH's haploidentical transplant protocol — widely known as the Peking Protocol — has been adopted at transplant centres globally. Understanding what makes it distinct explains PKUPH's position as the centre of choice for patients without a matched donor.

FeaturePeking Protocol (PKUPH)Traditional MUD Transplant
Donor typeHaploidentical (half-matched) — parent, sibling, adult childFully matched unrelated donor (MUD, 8/8 or 10/10 HLA match)
Donor availabilityAlmost universal — ~95% of patients have a haploidentical family donorLimited by registry size — significant shortage for non-Caucasian patients
GvHD preventionT-replete graft with combination ATG, CSA, MMF, and MTX post-transplant prophylaxis (no T-cell depletion of graft)T-replete MUD with standard prophylaxis or some T-cell depletion approaches
GvHD ratesGrade 2–4 acute GvHD: ~40%; Grade 3–4: ~15%; comparable to MUD in high-volume seriesGrade 2–4 acute GvHD: ~35–45% with standard MUD; variable by centre
Overall survival (ALL adults)2-year OS ~55–65% in MRD-negative CAR-T → haplo-SCT series2-year OS ~50–60% in MRD-negative CAR-T → MUD SCT series
Key publicationsHuang et al, Blood 2019; multiple PKUPH collaborative group series in Blood, Bone Marrow Transplant, J Hematol OncolMultiple international cooperative group trials — ALLO, BMT CTN
GvL advantageHaploidentical donors may provide stronger GvL than MUD in some series — active area of investigationWell-established GvL effect; quantification varies by conditioning intensity and disease

The CAR-T to Haploidentical Transplant Sequence at PKUPH

The complete pathway from CAR-T infusion to haploidentical transplant and post-transplant monitoring — typically completed over 3–6 months from leukapheresis.

  1. 1

    CAR-T Infusion and MRD-Negative Remission (Weeks 1–6)

    CD19 (or dual CD19+CD22) CAR-T is infused at the selected Chinese centre. Bone marrow aspirate with MRD assessment at day 28 and day 60. MRD-negative CR (flow cytometry <0.01%, PCR negative) is the target — achieved in 70–90% of patients. Start donor workup simultaneously.

  2. 2

    Donor Selection and HLA Typing (Weeks 2–8)

    With haploidentical transplant, the donor is a first-degree family member — parent, sibling, or adult child. HLA typing of available family members is performed. Donor selection considers HLA match within the haploidentical framework, donor age, health, ABO compatibility, and CMV status.

  3. 3

    Pre-Transplant Assessment (Weeks 6–10)

    Patient undergoes comprehensive transplant fitness assessment at PKUPH — LVEF, pulmonary function, renal and hepatic function, infectious screening, and dental review. Conditioning regimen and GvHD prophylaxis are planned based on patient and donor characteristics.

  4. 4

    Conditioning Chemotherapy and Stem Cell Infusion (Week 10–12)

    Myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) is administered over 7–10 days before stem cell infusion. PKUPH uses MAC for most r/r ALL patients — busulfan-based or TBI-based conditioning. Donor PBSCs or bone marrow cells are infused on day 0.

  5. 5

    Engraftment and Early GvHD Management (Weeks 12–20)

    Neutrophil engraftment typically occurs at day 14–21. GvHD prophylaxis (ATG, CSA, MMF, short-course MTX) continues. Grade 1–2 acute GvHD is managed with topical or low-dose systemic steroids; Grade 3–4 requires intensified immunosuppression. Chimerism testing at day 30 and 100.

  6. 6

    MRD Monitoring and GvL Maintenance

    Bone marrow MRD testing at day 30, 60, 100, and 180 post-transplant. Immunosuppression tapering from day 100 to promote GvL. Donor lymphocyte infusion (DLI) may be used for molecular relapse or impending mixed chimerism — a key PKUPH tool for post-transplant disease control.

Who Needs Transplant After CAR-T — and Who Might Not?

Transplant consolidation is standard for most adult ALL patients after CAR-T CR — but the evidence for all patient groups is not identical.

Transplant Strongly Recommended

  • Adult r/r ALL with MRD-negative CR after CAR-TThe primary population — adult patients achieving MRD-negative CR with CAR-T should proceed to allo-SCT unless significant comorbidity makes transplant risk unacceptable. This is the most strongly evidence-supported indication.
  • ALL with high-risk cytogenetics or molecular featuresPh+ ALL (BCR::ABL1), Ph-like ALL, complex karyotype, or MLL rearrangement — high biological relapse risk makes transplant consolidation essential even in patients achieving deep CAR-T responses.
  • Post-allo-SCT relapse achieving CR with CAR-TSecond transplant after CAR-T-induced CR in post-transplant relapse is feasible at PKUPH — typically from a different donor (family member if first transplant was MUD, or vice versa). Outcomes are lower than first transplant but represent a genuine long-term cure option.

Transplant May Be Deferred or Discussed

  • Paediatric ALL in first relapse — selected low-risk subgroupsChildren with good-risk features, including WNT-activated profiles and sustained deep MRD negativity at day 90+, may be candidates for CAR-T without transplant in some paediatric protocols — discussed in MDT.
  • Significant comorbidity making transplant-related mortality unacceptably highPatients with severe pre-existing organ dysfunction, poor performance status, or significant comorbid conditions may have transplant-related mortality that exceeds the relapse risk without SCT — requires individualised MDT decision.
  • Patient preference and quality of life — fully informed discussion requiredTransplant carries 10–20% treatment-related mortality and significant morbidity from GvHD. Some patients, after full information, prefer to accept higher relapse risk rather than transplant morbidity. This is a valid autonomous choice when all risks are understood.

Frequently Asked Questions

Common questions about CAR-T to haploidentical transplant planning at PKUPH.

About CAR-T Bridge to Haplo-SCT at PKUPH

  • My ALL achieved remission with CAR-T in my home country — can I come to PKUPH just for the transplant?

    Yes — this is one of the most common pathways CancerFax manages. Patients who have received CAR-T at a local centre and achieved MRD-negative CR can be referred to PKUPH specifically for haploidentical transplant consolidation. CancerFax coordinates the transfer of treatment records, MRD documentation, and donor HLA typing to PKUPH for pre-transplant assessment — and manages the full logistics of the transplant admission.

  • How long does a patient need to stay in China for the transplant process?

    The haploidentical transplant process at PKUPH typically requires 60–90 days from conditioning start to discharge. The early post-transplant period (days 0–30) requires inpatient admission; from day 30–60, most patients can transition to daily outpatient assessment before discharge. CancerFax coordinates accommodation near PKUPH for patients and accompanying family, and provides daily coordination support throughout the stay.

  • What if I develop GvHD after haploidentical transplant at PKUPH?

    GvHD is managed by PKUPH's experienced transplant team — one of the most experienced in the world for haploidentical transplant GvHD. The Peking Protocol's GvHD prophylaxis regimen has been specifically designed to achieve acceptable GvHD rates. For international patients who need to return home before full immunosuppression taper, CancerFax coordinates detailed GvHD management protocols with the home haematologist to ensure continuity of prophylaxis and monitoring.

  • Is haploidentical transplant after CAR-T as good as matched transplant?

    Published comparative data suggests equivalent outcomes between haploidentical and MUD transplants in patients achieving MRD-negative CR with CAR-T before SCT. PKUPH has published multiple series comparing haplo and MUD in ALL — showing no significant difference in 2-year OS or relapse rate when controlling for disease status at transplant. The critical variable is disease status at transplant (MRD-negative is essential), not donor type.

More from the CAR-T Cell Therapy Resource Library

Continue exploring CAR-T guides for ALL, DLBCL, and myeloma.

How CancerFax Helps

CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.

description
Medical Record Review

We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.

verified_user
Eligibility Coordination

We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.

hub
Hospital Communication

We support appointment coordination, document submission, translation, and direct communication with international departments.

flight
Travel & Admission Support

For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.

explore
Treatment & Trial Navigation

If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.

support_agent
End-to-end Coordination

From inquiry through to follow-up, our coordinators provide a single point of contact for the family.

Send Medical ReportsSpeak With CancerFax

CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.

Plan Your CAR-T to Transplant Pathway Through CancerFax

CancerFax coordinates the complete pathway — CAR-T at an appropriate Chinese centre, MRD assessment, donor identification, and haploidentical transplant at PKUPH — for ALL patients seeking the best available chance at long-term remission.

Send Your ReportsContact Us

This content is for informational purposes only. Treatment planning must involve a qualified haematologist and transplant physician.